Like peas in a pod
نویسندگان
چکیده
In January, Harold Varmus will begin the next stage in an unusual career. He’s gone from English literature to medicine to bench science to Washington science bureaucrat, and now he becomes the well-paid (some would say extremely well-paid) president of a private, not-for-profit treatment and research facility, the Memorial Sloan Kettering Cancer Center in New York. He’s succeeded in everything else he’s tried, so it’s a good bet he’ll succeed in this latest role, too. It might seem like the jump from English to medicine was the biggest one, but Varmus will tell you that an even bigger leap was going from scientist to science bureaucrat. By his own admission, just a few years before becoming director of the NIH in 1992 his interest in the politics of science was practically non-existent. He was running a successful lab at the University of California, San Francisco and, with Michael Bishop, he won the 1989 Nobel Prize for Physiology or Medicine for his work on viruses and their relationship to oncogenes. But as he tells it, in the late 1980s and early 1990s, several events occurred that brought Varmus off the political sidelines. First, a quirk in funding patterns led to an unusually low success rate for new grants, especially among first-time applicants. Second, there was a series of misconduct scandals that seemed to tarnish the public’s traditionally high regard for scientists. And finally, the Reagan administration seemed bent on shifting the support for science from basic to applied research as a way of justifying the multi-billion dollar federal research budget. Varmus felt he couldn’t sit idly by in the face of these threats. What’s more, his newly bestowed Nobel Prize gave him unusual access to both the media and the political establishment. Varmus entered the fray. In part, he blames two people for getting him engaged: his colleagues Marc Kirschner and Bruce Alberts, both then at UCSF. Varmus says Alberts in particular convinced him to take a more active role in solving the funding problems facing scientists. And, says Varmus, “when Bruce, as newly elected President of the NAS, was asked to chair a search committee to find a new NIH Director, my fate was sealed.” Although outsiders are frequently hauled into Washington, it’s rare to put someone at the top of an 11 billion dollar federal agency with no experience of managing anything larger than a personal laboratory. But those who knew him were convinced Varmus could accomplish anything he set his mind to. “I think Harold not only proved us all right,” says UCSF’s Keith Yamamoto, “but far exceeded anything any of us expected. He turned out not only to be a capable administrator, even though he lacked that experience, but he has just done a masterful job.” Yamamoto says being NIH director did not change Varmus’ style all that much. “What Harold did was to go there as a scientist and say, ‘look, we can do things the way we do in the laboratory, we can do experiments, and if they work, we can implement them.’’ Yamamoto says one of his big achievements was to start to overhaul the peer review process for approving grants. According to Yamamoto the new system will allow for more innovative if more risky research to have a better chance of being funded. Another project with broad implications is Varmus’ plan to put all biomedical research papers online — by means of the new NIH publishing venture, PubMed Central. Tom Pollard, the president of the Salk Institute in La Jolla, says the project reflects the kind of forward thinking Varmus is capable of. “The idea is to allow the scientific community all around the world access to the major publications in an electronic form so that anybody could have access to any piece of information without restriction, whether they were in a small institution here in the US or in any other part of the world.” PubMed Central will be launched early next year by the NIH, albeit as a somewhat watered-down version of the original idea. Although Varmus won widespread praise for his leadership at NIH, both from politicians and fellow science bureaucrats, he never stopped behaving more like a scientist. He maintained an active laboratory within the National Cancer Institute, and rode his bicycle to work, frequently showing up at his office in sweaty clothes, changing into a suit only if the day’s activities required. Varmus is an intense man — not surprising considering all he manages to accomplish in a given day. He can intimidate lesser minds, and has little patience for sloppy thinking. “He’s not what I would describe as cuddly,” remarks one senior NIH official, “but if he thinks you’re right, he’ll be one of your fiercest defenders.” Magazine R907
منابع مشابه
Nuclear Dimorphism: Two Peas in a Pod
The macro- and micronuclei of Tetrahymena reside in the same cytoplasm but are about as different as night and day. This extreme case of nuclear dimorphism can now be partially attributed to differences in the subunit compositions of their nuclear pore complexes.
متن کاملPrinciples of Inheritance and Variation
Gregor Mendel. Conducted hybridization experiments on garden peas for seven years (1856 – 1863) and proposed laws of inheritance. Mendel conducted artificial pollination/cross pollination experiments using several true-breeding pea lines. A true breeding line is one that, having undergone continuous self-pollination for several generations. Mendel selected 14 true-breeding peas’ plant v...
متن کاملThe application of individually and socially distributed cognition in workplace studies: two peas in a pod?
This paper compares and contrasts two forms of distributed cognition one looking at how an individual interacts with one or more artefacts, the other looking at how groups of people interact with or without artefacts. Whilst the two approaches have many similarities, they can be seen to have significant practical and theoretical differences and merit very different approaches, particularly in t...
متن کاملCTAD 2012 in Monte Carlo : Getting Preclinical
Turning the Ship Around Toward Early Trials In a place where yachts sit jammed side by side in the harbor like so many gilded peas in a pod, a marine metaphor seems fitting. The conference showcased a field trying to steer therapy development out of the doldrums of the past decade and into swifter waters. Organized by Bruno Vellas of the University of Toulouse, Jacques Touchon of Montpellier Un...
متن کاملMetabolic syndrome and hypogonadism--two peas in a pod.
Testosterone deficiency is highly prevalent in up to 50% of men with the metabolic syndrome and type 2 diabetes mellitus. Low testosterone levels in men appear to be an independent cardiovascular risk factor and predictor of subsequent development of the metabolic syndrome. Reciprocally, the metabolic syndrome leads to a decrease in testosterone levels. This review provides an account of the pa...
متن کاملEDTA a novel inducer of pisatin, a phytoalexin indicator of the non-host resistance in peas.
Pea pod endocarp suppresses the growth of an inappropriate fungus or non-pathogen by generating a "non-host resistance response" that completely suppresses growth of the challenging fungus within 6 h. Most of the components of this resistance response including pisatin production can be elicited by an extensive number of both biotic and abiotic inducers. Thus this phytoalexin serves as an indic...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Current Biology
دوره 9 شماره
صفحات -
تاریخ انتشار 1999